Asahi Kasei Acquires Aicuris for €780 Million
Asahi Kasei will acquire all shares in the German biopharmaceutical company Aicuris Anti-infective Cures for approximately €780 million.
With this transaction, which is expected to be completed in the first quarter of fiscal year 2026, Asahi Kasei's specialty pharma platform continues to expand in the therapeutic area for the treatment of severe infectious diseases.
With this acquisition, Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharma platform for immunocompromised and medically complex patient populations. Severe infectious diseases are an area strategically adjacent to Asahi Kasei's established core areas of transplantation (Veloxis) and nephrology (Calliditas), where infection-related complications continue to be a significant clinical problem.
By leveraging its established commercial infrastructure in transplant centers and nephrology providers, as well as its advanced research and development capabilities, Asahi Kasei expects to accelerate the development and commercialization of Aicuris' product pipeline. At the same time, it will increase operational efficiency and long-term returns.
“This acquisition strengthens our position across interconnected therapeutic areas, including autoimmune diseases, transplantation, kidney disease, and severe infectious diseases. It enhances our pipeline and reinforces our strategy to build a leading global specialty pharmaceutical company,” stated Ken Shinomiya, Head of Asahi Kasei’s Healthcare Sector. “Given the strategic alignment of this asset and the opportunity to expand within an area where we already have an established presence, we acted in a nimble and disciplined manner to advance our long-term growth objectives. This transaction accords with our capital allocation framework and supports our objective of achieving net sales of ¥300 billion in Pharmaceuticals with an operating margin of 15% or higher by fiscal 2030.”
